Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesCardiologyQualChoice Myqorzo (aficamten) Coverage Prior Auth…
    Ask Trek AI about this page
    CurrentQualChoicePolicy CP.PHAR.766

    Aficamten (Myqorzo) coverage

    Customize your policy alerts

    Sign up for QualChoice Policy CP.PHAR.766 alerts

    Get alerted when Policy CP.PHAR.766 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity and prior authorization criteria for Aficamten (Myqorzo) for adults with symptomatic obstructive hypertrophic cardiomyopathy across QualChoice lines of business.

    Policy Summary
    PayerQualChoice
    PolicyAficamten (Myqorzo) coverage
    Policy CodePolicy CP.PHAR.766
    Change TypeMinor / no material change
    Effective DateMar 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with documentation that all approval criteria are met, including diagnosis, NYHA class, cardiology involvement, LVEF, LVOT gradients, and prior therapy history.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ≥18min age
    ≥55%LVEF req
    ≤20 mg/daymax daily dose
    12 moauth duration
    Fail 2 agents

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    step therapy

    Coverage Criteria for Aficamten (Myqorzo)

    inv-01: Initial Therapy — Obstructive Hypertrophic Cardiomyopathy

    Covered when ALL of the following are met:

    Initial oHCM coverage criteria: 1. Diagnosis of obstructive hypertrophic cardiomyopathy (oHCM). 2. Member exhibits NYHA Class II–III symptoms (e.g., effort-related dyspnea, chest pain, syncope or near-syncope) attributed to left ventricular outflow tract obstruction. 3. Prescribed by or in consultation with a cardiologist. 4. Age ≥ 18 years. 5. Left ventricular hypertrophy with maximal LV wall thickness: a) ≥ 15 mm; OR b) ≥ 13 mm if familial HCM or with a positive genetic test. 6. Left ventricular ejection fraction (LVEF) ≥ 55%. 7. Peak LVOT gradients meet BOTH: a) ≥ 30 mmHg at rest; AND b) ≥ 50 mmHg with provocation. 8. Failure of TWO of the following at up to maximally indicated doses unless contraindicated or clinically significant adverse effects: a) non-vasodilating beta-blocker (e.g., atenolol, metoprolol, bisoprolol, propranolol); b) non-dihydropyridine calcium channel blocker (e.g., verapamil, diltiazem); c) add-on disopyramide after failure of beta-blocker or calcium channel blocker monotherapy. 9. Myqorzo (aficamten) is not prescribed concurrently with Camzyos®. 10. Proposed dose does not exceed 20 mg per day.all criteria must be met

    Approval duration 12 months

    inv-02: Continued Therapy — Obstructive Hypertrophic Cardiomyopathy

    Covered when ALL of the following are met:

    Continuation criteria: 1. Member meets one of the following: a) currently receiving medication via Centene benefit or previously met initial approval criteria; OR b) currently receiving medication and enrolled in a state/product with continuity of care regulations. 2. Member is responding positively to therapy as evidenced by improvement in obstructive HCM symptoms. 3. Myqorzo (aficamten) is not prescribed concurrently with Camzyos®. 4. If the request is for a dose increase, the new dose does not exceed 20 mg per day.all criteria must be met

    Approval duration 12 months

    inv-03: Other Diagnoses/Indications

    Requests for uses not specifically listed

    Alternative handling: 1. If the drug label has changed within the last 6 months and this policy is not yet updated, follow one of: a) for drugs on the formulary/PDL, the applicable no coverage criteria policy (e.g., CP.CPA.190, HIM.PA.33, CP.PMN.255); OR b) for drugs not on the formulary/PDL, the applicable non-formulary policy (e.g., CP.CPA.190, HIM.PA.103, CP.PMN.16). 2. If the requested use (diagnosis, age, dosing regimen) is not listed under section III and criterion 1 does not apply, refer to the off-label use policy for the relevant line of business (e.g., CP.CPA.09, HIM.PA.154, CP.PMN.53).either pathway

    Refer to the listed formulary/non-formulary or off-label policies as applicable

    Coverage is not authorized for non-FDA approved indications that are not specifically addressed in this policy unless there is sufficient documentation of efficacy and safety in accordance with the applicable off‑label use policies (see CP.CPA.09 for Commercial, HIM.PA.154 for Health Insurance Marketplace, and CP.PMN.53 for Medicaid) or other evidence of coverage documents.

    Use of aficamten (Myqorzo) for non-FDA approved indications is considered not medically necessary unless the provider supplies sufficient clinical evidence or documentation consistent with the insurer's off‑label use policies. Initiation of therapy is not recommended when left ventricular ejection fraction (LVEF) is < 55% per the boxed warning and REMS requirements; dose reductions or interruptions are required at lower LVEF thresholds as specified by the product labeling.

    Dosing, Thresholds, and Coding Details

    Maximum daily dose
    Maximum daily dose20 mg per day
    Approval duration12 months
    Age requirementPatient must be ≥ 18 years
    Initiation dose and titration
    Initiation doseInitiate 5 mg PO once daily
    Titration scheduleIncrease by 5 mg every 2 to 8 weeks to a maintenance dose individualized by LVEF and LVOT gradient
    Maximum recommended doseTitrate up to a maximum of 20 mg PO once daily

    Required Provider Actions and Documentation

    Prior Authorization

    Prior authorization required

    Prior authorization is required. Submit documentation demonstrating all approval criteria are met, including diagnosis of obstructive HCM, NYHA Class II–III symptoms, that the prescriber is a cardiologist or consulted with one, age ≥18, LV measurements (wall thickness and LVOT gradients), LVEF, prior therapy failures, and that Myqorzo is not prescribed concurrently with Camzyos; approval duration is 12 months.

    • Documentation must show LV hypertrophy criteria, LVEF ≥55%, and peak LVOT gradients (≥30 mmHg at rest and ≥50 mmHg with provocation).
    • Ensure absence of concurrent Camzyos® use and that dose does not exceed 20 mg/day.
    Step Therapy

    Step therapy — failure of 2 medication classes

    Initial approval requires documented failure of TWO agents at up to maximally indicated doses (unless contraindicated or adverse effects): a non-vasodilating beta-blocker, a non-dihydropyridine calcium channel blocker, or add-on disopyramide after beta-blocker or CCB monotherapy failure.

    Background

    Aficamten (Myqorzo) is a cardiac myosin inhibitor approved to improve functional capacity and symptoms in adults with symptomatic obstructive hypertrophic cardiomyopathy. The drug carries a boxed warning for risk of heart failure due to systolic dysfunction and is available only through the Myqorzo REMS Program. Baseline and ongoing echocardiographic monitoring of LVEF is required; initiation is not recommended if LVEF < 55%, decrease dose if LVEF is <50% and ≥40%, and interrupt dosing if LVEF is <40% or if there is worsening clinical status.

    Definitions and Clinical Classifications

    oHCM
    Definition — oHCMObstructive hypertrophic cardiomyopathy characterized by left ventricular hypertrophy and left ventricular outflow tract (LVOT) obstruction with symptomatic NYHA Class II–III
    Required symptomsSymptoms include effort-related dyspnea, chest pain, syncope or near-syncope attributed to LVOT obstruction
    Specialist involvementDiagnosis and prescribing should involve a cardiologist (prescribed by or in consultation with a cardiologist)
    NYHA Class II–III
    NYHA Class requiredNYHA Class II–III symptomatic classification required for this policy
    Examples of symptomsIncludes effort-related dyspnea or chest pain, syncope or near-syncope attributed to LVOT obstruction
    Policy Summary
    PayerQualChoice
    PolicyAficamten (Myqorzo) coverage
    Policy CodePolicy CP.PHAR.766
    Change TypeMinor / no material change
    Effective DateMar 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with documentation that all approval criteria are met, including diagnosis, NYHA class, cardiology involvement, LVEF, LVOT gradients, and prior therapy history.
    SourceLink
    On This Page
    Coverage Criteria for Aficamten (Myqorzo)Dosing, Thresholds, and Coding DetailsRequired Provider Actions and DocumentationBackgroundDefinitions and Clinical Classifications
    LVEF thresholds for dosing actions
    Recommended LVEF for initiationInitiation not recommended if LVEF < 55% (initiation requires LVEF ≥ 55%)
    Dose reduction thresholdDecrease dose if LVEF < 50% and ≥ 40% (decrease by 5 mg per dosing guidance)
    Treatment interruption thresholdInterrupt dosing if LVEF < 40% or with worsening clinical status (interrupt for at least 7 days as specified)
    LV wall thickness
    LV wall thickness — general thresholdMaximal left ventricular wall thickness ≥ 15 mm
    LV wall thickness — familial/geneticThreshold ≥ 13 mm if familial HCM or in conjunction with a positive genetic test
    DocumentationWall thickness requirement referenced in initial approval criteria (see Appendix D for details)
    LVOT gradient requirements
    Resting LVOT gradientPeak LVOT gradient ≥ 30 mmHg at rest
    Provoked LVOT gradientPeak LVOT gradient ≥ 50 mmHg with provocation
    Both conditions requiredPolicy requires both resting ≥30 mmHg AND provoked ≥50 mmHg for approval
    • Examples include atenolol, metoprolol, bisoprolol, propranolol (beta-blockers) and verapamil or diltiazem (non-dihydropyridine CCBs).
    • For Illinois HIM requests, step therapy requirements do not apply as of 1/1/2026 per IL HB 5395.
    Documentation Required

    Submit required clinical documentation

    Provider must submit supporting clinical documentation with the prior authorization request such as office chart notes, laboratory results, and echocardiogram reports that document LVEF, LV wall thickness, and peak LVOT gradients, as well as records of prior therapies and NYHA symptom class.

    • Include echocardiogram assessments showing LVEF and LVOT gradients and documentation of maximal wall thickness (≥15 mm or ≥13 mm with familial HCM/positive genetic test).
    • Provide evidence of prior therapy attempts and the member’s NYHA Class II–III symptoms.
    Denial Risk

    LVEF must meet initiation and monitoring thresholds

    Requests may be denied if LVEF is below policy thresholds; initiation is not recommended when LVEF <55%. REMS requires baseline and ongoing echocardiographic LVEF monitoring with specified dose adjustments for reduced LVEF.

    • Do not initiate Myqorzo if LVEF <55%. Decrease dose if LVEF <50% and ≥40%; interrupt dosing if LVEF <40% or if worsening clinical status.
    • Echocardiogram assessments of LVEF are required before and during Myqorzo use per the REMS program.
    Denial Risk

    Denial risk if clinical criteria are not documented

    Requests may be denied if documentation does not demonstrate required clinical criteria, including NYHA Class II–III symptoms, LV wall thickness, peak LVOT gradients, or required prior therapy failures.

    • Ensure documentation of NYHA symptom class attributed to LVOT obstruction and LV hypertrophy (≥15 mm or ≥13 mm with familial HCM/positive genetic test).
    • Provide peak LVOT gradients showing ≥30 mmHg at rest and ≥50 mmHg with provocation, and evidence of two failed therapies unless contraindicated.
    Use in criteriaNYHA Class II–III is used to assess functional limitation due to cardiac disease and is a required element of initial approval